Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.73 |
| ▸ | PRTN3 | P24158 | 3/20 | 0.73 |
| ▸ | CTSG | P08311 | 2/20 | 0.73 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8320094 | 0.83 | ELANE (0.73) | ELANEPRTN3CTSGNR3C2LMNA | |
| SCHEMBL10508524 | 0.74 | ELANE (0.46) | ELANEPRTN3CTSGLMNACTSK | |
| Ethadione SCHEMBL35279 | 0.70 | ELANE (0.55) | ELANEPRTN3CTSGLMNAPGR | |
| SCHEMBL4914804 | 0.70 | ELANE (0.63) | ELANEPRTN3CTSGNR3C2LMNA | |
| SCHEMBL5006337 | 0.69 | ELANE (0.54) | ELANEPRTN3CTSGLMNACTSK | |
| SCHEMBL4757301 | 0.69 | ELANE (0.53) | ELANEPRTN3CTSGLMNAGRM2 | |
| SCHEMBL7309157 | 0.69 | ELANE (0.53) | ELANEPRTN3CTSGLMNAGRM2 | |
| SCHEMBL6642820 | 0.68 | ELANE (0.49) | ELANEPRTN3CTSGLMNACTSK | |
| SCHEMBL14009928 | 0.67 | LMNA (0.54) | ELANEPRTN3CTSGLMNAPGR | |
| SCHEMBL4457536 | 0.67 | CA12 (0.53) | ELANECTSGALDH1A1MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | claimed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | claimed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | claimed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | claimed |
| EP-1592426-B1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
| EP-1592426-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069256-A1 | 2-CYANOPYRROLOPYRIMIDINES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247251-A1 | 2-Cyanopyrrolopyrimidines and pharmaceutical uses thereof | DPYD, P2RY1, P2RY2 | ELANE 4815/4885PRTN3 4022/4885CTSG 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.